On 25 September 2010, China’s State Food and Drug Administration (SFDA) issued new guidance for industry for submission of new drug applications (NDAs) in the common technical document (CTD) format.
China’s regulatory authority adopt CTD format for NDAs
Home/Guidelines | Posted 25/03/2011 0 Post your comment
The new guidance was issued, according to the SFDA, in order to improve the quality and level of drug research and development in China and continues China’s trend of integrating with international regulatory standards.
The new guidance: ‘Requirements on Application Dossiers in CTD Format for Pharmaceutical Products’ is based on the CTD of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use (ICH), in combination with the actual situation of drug research and development in China.
However, there is a caveat to this news as the SFDA still states as an addendum to the guidance that Attachment 2 of the ‘Provisions for Drug Registration’ SFDA Order No. 28 must still be referenced, meaning that NDAs must still use Attachment 2 as the primary guide.
The CTD has already been developed for Japan, the EU and the US through the ICH process, and India has also issued guidance for submissions in the CTD format.
The guidance document and Attachment 2 are available on the website of the SFDA.
Related article
India regulatory authority to adopt CTD format for NDAs
Source: SFDA
Policies & Legislation
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
WHO’s revised guideline to safe and effective biosimilar products
New FDA guidance on statistical approaches to establishing bioequivalence
Comments (0)
Post your comment